21 February 2025
21 February 2025
AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney disease.
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and development timeline.
BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
Genesis will obtain a $30m upfront payment and the collaboration will initially focus on two targets.
How can pharmaceutical firms shore up their sustainability credentials at a time when the entire research landscape is turning on its head? A recent webinar from supply chain leaders World Courier and Cencora offered answers
The decision is underpinned by safety and efficacy data from the international Phase III VANGUARD trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
